Viatris (VTRS) Common Equity (2019 - 2026)
Viatris (VTRS) posted Common Equity of $14.3 billion for Q2 2026, down 2.71% on a QoQ basis from $14.7 billion in Q1 2026, and down 8.41% year-over-year from $15.6 billion in Q2 2025.
Analysis
Viatris (VTRS) Common Equity (2019 - 2026) Analysis & Trends
Viatris has reported Common Equity for 8 years, with the latest figure at $14.3 billion in Q2 2026.
- On a quarterly basis, Common Equity fell 8.41% year-over-year to $14.3 billion in Q2 2026; TTM through Jun 2026 was $14.3 billion, a 8.41% decrease from a year earlier, with the FY2025 full-year figure at $14.7 billion, down 21.06% from the prior year.
- Common Equity was $14.3 billion for Q2 2026 at Viatris, down from $14.7 billion in the prior quarter.
- The five-year high for Common Equity was $21.1 billion in Q4 2022, with the low at $14.3 billion in Q2 2026.
- Average Common Equity over 5 years is $18.4 billion, with a median of $19.7 billion recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Common Equity grew 8.78% in 2023, then retreated 23.11% in 2025.
- Over 5 years, Common Equity stood at $21.1 billion in 2022, then decreased by 2.87% to $20.5 billion in 2023, then retreated by 8.95% to $18.6 billion in 2024, then dropped by 21.06% to $14.7 billion in 2025, then declined by 3.06% to $14.3 billion in 2026.
- The last three Common Equity figures came in at $14.3 billion (Q2 2026), $14.7 billion (Q1 2026), and $14.7 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 7.76 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 14.26 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 4.08 Bn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 33.02 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | -1.77 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -191.48 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 597.21 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 768.16 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 42.44 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 4.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.26 Bn |
| Mar 31, 2026 | 14.66 Bn |
| Dec 31, 2025 | 14.71 Bn |
| Sep 30, 2025 | 15.22 Bn |
| Jun 30, 2025 | 15.57 Bn |
| Mar 31, 2025 | 15.65 Bn |
| Dec 31, 2024 | 18.64 Bn |
| Sep 30, 2024 | 19.79 Bn |
| Jun 30, 2024 | 19.52 Bn |
| Mar 31, 2024 | 20.01 Bn |
| Dec 31, 2023 | 20.47 Bn |
| Sep 30, 2023 | 20.87 Bn |
| Jun 30, 2023 | 20.84 Bn |
| Mar 31, 2023 | 20.93 Bn |
| Dec 31, 2022 | 21.07 Bn |
| Sep 30, 2022 | 19.18 Bn |
| Jun 30, 2022 | 19.81 Bn |
| Mar 31, 2022 | 20.45 Bn |
| Dec 31, 2021 | 20.49 Bn |
| Sep 30, 2021 | 21.14 Bn |